Table 1.
Examples of TRPV1 antagonists in clinical development. (Current status determined from sponsor's website and/or press releases or publications.)
| Compound | Sponsor | Clinical phase | Current status | Last reported clinical results |
|---|---|---|---|---|
| ABT-102 | Abbott | 1 | Discontinued | 2013 |
| AMG 517 | Amgen | 2 | Discontinued | 2008 |
| AZD1386 | AstraZeneca | 2 | Discontinued | 2014 |
| GRC-6211 | Lilly-Glenmark | 2 | Discontinued | 2008 |
| JNJ-39439335 (Mavatrep) | J&J | 1 | Discontinued | 2009 |
| MK-2295 / NGD-8243 | Merck-Neurogen | 2 | Discontinued | 2011 |
| NEO6860 | NeoMed | 2 | Ongoing | 2017 |
| PAC-14028 | AmorePacific | 2 | Ongoing | 2017 |
| SB-705498 | GSK | 2 | Discontinued | 2014 |
| Unnamed | Evotec | 1 | Discontinued | 2009 |
| V116517 | Purdue Pharma | 2 | Discontinued | 2016 |
| XEN-D0501 | Pila Pharma (Xention) | 2 | Ongoing (diabetes) | 2011 |